Alnylam Pharmaceuticals (ALNY)
(Delayed Data from NSDQ)
$144.41 USD
-0.75 (-0.52%)
Updated Apr 19, 2024 04:00 PM ET
After-Market: $144.35 -0.06 (-0.04%) 7:58 PM ET
3-Hold of 5 3
D Value A Growth B Momentum B VGM
Alnylam Pharmaceuticals (ALNY) Price Targets
Average Price Target | Highest Price Target | Lowest Price Target | Upside to Average Price Target |
---|---|---|---|
$218.91 | $395.00 | $136.00 | 50.81% |
Price Target
Based on short-term price targets offered by 22 analysts, the average price target for Alnylam Pharmaceuticals comes to $218.91. The forecasts range from a low of $136.00 to a high of $395.00. The average price target represents an increase of 50.81% from the last closing price of $145.16.
Analyst Price Targets (22)
Broker Rating
Alnylam Pharmaceuticals currently has an average brokerage recommendation (ABR) of 1.84 on a scale of 1 to 5 (Strong Buy to Strong Sell), calculated based on the actual recommendations (Buy, Hold, Sell etc.) made by 25 brokerage firms. The current ABR compares to an ABR of 1.84 a month ago based on 25 recommendations.
Of the 25 recommendations deriving the current ABR, 13 are Strong Buy and three are Buy. Strong Buy and Buy respectively account for 52% and 12% of all recommendations. A month ago, Strong Buy made up 52%, while Buy represented 12%.
Broker Rating Breakdown
Brokerage Recommendations
Today | 1 Week Ago | 1 Month Ago | 2 Months Ago | 3 Months Ago | |
---|---|---|---|---|---|
Strong Buy | 13 | 13 | 13 | 13 | 14 |
Buy | 3 | 3 | 3 | 3 | 3 |
Hold | 9 | 9 | 9 | 9 | 7 |
Sell | 0 | 0 | 0 | 0 | 0 |
Strong Sell | 0 | 0 | 0 | 0 | 0 |
ABR | 1.84 | 1.84 | 1.84 | 1.84 | 1.71 |
1. Not Ident. Many of the brokerage firms who provide Zacks data ask that we keep their identity confidential.
2. In most cases the # of brokers listed above is less than the # of brokerage firms that have a recommendation on the stock. That is because some firms prohibit Zacks from displaying detailed information on their recommendations such as in the upgrade/downgrade table.
Analyst Upgrades/Downgrades
Date | Brokerage Firm | Analyst | Previous | Current |
---|---|---|---|---|
4/12/2024 | SVB Securities | Mani Foroohar | Hold | Hold |
4/8/2024 | William Blair | Myles R Minter | Strong Buy | Strong Buy |
3/27/2024 | BMO Capital Markets | Kostas Biliouris | Strong Buy | Strong Buy |
3/5/2024 | H.C. Wainwright & Co. | Patrick Trucchio | Strong Buy | Strong Buy |
2/16/2024 | Chardan Capital Markets | Keay T Nakae | Strong Buy | Strong Buy |
2/15/2024 | Needham & Company | Joseph R Stringer | Moderate Buy | Moderate Buy |
12/14/2023 | Canaccord Genuity | Whitney Ijem | Strong Buy | Strong Buy |
12/14/2023 | Piper Sandler | Edward A Tenthoff | Strong Buy | Strong Buy |
12/14/2023 | Cantor Fitzgerald & Co | Olivia Brayer | Hold | Hold |
12/1/2023 | Guggenheim Securities | Debjit Chattopadhyay | Hold | Hold |
9/29/2023 | Raymond James | Gary Nachman | Moderate Buy | Moderate Buy |
1. Not Ident. Many of the brokerage firms who provide Zacks data ask that we keep their identity confidential.
2. In most cases the # of brokers listed above is less than the # of brokerage firms that have a recommendation on the stock. That is because some firms prohibit Zacks from displaying detailed information on their recommendations such as in the upgrade/downgrade table.
Average Brokerage Rating
Current ABR | 1.84 |
ABR (Last week) | 1.84 |
# of Recs in ABR | 25 |
Average Target Price | $218.91 |
LT Growth Rate | NA |
Industry | Medical - Biomedical and Genetics |
Industry Rank by ABR | 86 of 252 |
Current Quarter EPS Est: | -0.75 |